Iterum Therapeutics Non-GAAP EPS of -$0.13

* Iterum Therapeutics press release [https://seekingalpha.com/pr/20188670-iterum-therapeutics-reports-second-quarter-2025-financial-results] (NASDAQ:ITRM [https://seekingalpha.com/symbol/ITRM]): Q2 Non-GAAP EPS of -$0.13.
* Cash and cash equivalents were $13.0 million as of June 30, 2025. Based on Iterum’s current operating plan, Iterum expects that its cash and cash equivalents as of June 30, 2025, together with $2.2 million of net proceeds raised under its at-the-market offering program from July 1, 2025 through August 1, 2025, will be sufficient to fund its operations into 2026. The foregoing estimate gives effect to Iterum’s currently planned commercial launch of ORLYNVAHTM in August 2025. As of August 1, 2025, Iterum had approximately 44.7 million ordinary shares outstanding.

MORE ON ITERUM THERAPEUTICS

* Iterum Therapeutics plc (ITRM) Q1 2025 Earnings Call Transcript [https://seekingalpha.com/article/4786175-iterum-therapeutics-plc-itrm-q1-2025-earnings-call-transcript]
* Iterum targets ORLYNVAH US launch by Q4 2025 while extending cash runway into 2026 [https://seekingalpha.com/news/4447379-iterum-targets-orlynvah-us-launch-by-q4-2025-while-extending-cash-runway-into-2026]
* Iterum Therapeutics Non-GAAP EPS of -$0.10 [https://seekingalpha.com/news/4447034-iterum-therapeutics-non-gaap-eps-of-0_10]
* Seeking Alpha’s Quant Rating on Iterum Therapeutics [https://seekingalpha.com/symbol/ITRM/ratings/quant-ratings]
* Historical earnings data for Iterum Therapeutics [https://seekingalpha.com/symbol/ITRM/earnings]